{"success":true,"data":{"pressRelease":{"id":"65043","rtpr_id":"nGNXxXDM","ticker":"ENTX","exchange":"NASDAQ","all_tickers":["ENTX","OPK","5DT"],"title":"Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026","author":"Globe Newswire","published_at":"2026-06-16T12:33:11.097Z","article_body":"EB612, a first-in-class long-acting PTH(1-34) oral peptide  for\nhypoparathyroidism, produced robust bioavailability and sustained increases in\ncalcium across three preclinical models; IND is expected in late 2026\n\nEB618, a first-in-class dual GLP-1/glucagon oral receptor agonist\n(oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional\npharmacokinetics and a robust effect on blood glucose in non-human primates\n\nTEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX)\n(“Entera”), a leader in the development of oral peptides, reported\npreclinical data at ENDO 2026, the annual meeting of the Endocrine Society,\nfor its EB612 and EB618 pipeline programs. Both EB612 and EB618 programs are\nbeing co-developed with OPKO Health Inc. (NASDAQ: OPK).\n\n“The strength of these results underscores the consistency of our N-Tab(®)\nplatform to develop proprietary oral peptides across a myriad of targets and\nindications,” said Miranda Toledano, Chief Executive Officer of Entera.\n\nEB612: First-in-Class Oral Long-Acting PTH(1-34) Peptide Tablet for\nHypoparathyroidism\n\nEB612 is a proprietary first-in-class long-acting PTH(1-34) analog formulated\nwith Entera’s N-Tab(®) oral peptide platform.  As the first oral peptide\nreplacement therapy, EB612 aims to provide patients with an oral alternative\nto currently approved or development-stage peptides that require injections.\n\nIn a poster presentation entitled “Pre-Clinical Results for EB612:\nFirst-in-Class Oral Long-Acting PTH(1-34) Analog as Hormone Replacement Tablet\nfor Patients with Hypoparathyroidism,” Entera highlighted the following data\nfor EB612:\n* In the thyroparathyroidectomized (TPTx) rat model, the established and\nwidely used preclinical model of hypoparathyroidism, the long-acting PTH(1-34)\nanalog, dosed daily for 7 days, restored serum calcium and reduced phosphate\nto levels comparable to sham control animals.\n* In a minipig model, a single oral dose of EB612 reached maximal plasma\nlevels 2 to 3 hours post-dose, with drug remaining detectable in plasma for\nmore than three days. This sustained pharmacokinetic exposure was associated\nwith a rapid and long-lasting increase in serum Ca in all study animals. The\ncalcemic effect lasted for approximately three days.\n* In a non-human primate model, a single oral dose of EB612 produced a robust\nand sustained increase in serum calcium for approximately three days,\naccompanied by a correlating suppression of endogenous PTH levels.\nEB612 was well tolerated, with no safety concerns identified, and the calcemic\neffects were consistent with those reported for clinically validated\ninjectable PTH-replacement therapies for hypoparathyroidism.\n\nOngoing studies are advancing EB612 toward first-in-human clinical evaluation.\nAs announced in February 2026, Entera and OPKO expanded their collaboration to\nadvance EB612 on a 50/50 basis, with an intention to file an investigational\nnew drug (IND) application in late 2026.\n\nEB618: First-in-Class Oral Dual GLP-1/Glucagon receptor agonist\n(Oxyntomodulin) Tablet for Obesity and Metabolic Disorders\n\nOxyntomodulin (OXM) is a naturally occurring dual GLP-1/glucagon receptor\nagonist hormone that regulates appetite and glucose metabolism and promotes\nweight loss, with additional cardioprotective and anti-fibrotic properties;\nits therapeutic potential as a native hormone is limited by a short plasma\nhalf-life.\n\nThe EB618 tablet is a proprietary long-acting OXM analog formulated with\nEntera’s N-Tab(®) platform.\n\nIn a poster presentation at ENDO 2026 entitled “EB618, First-In-Class Oral\nTablet of Dual GLP-1/Glucagon Receptor Agonist for Patients with Obesity and\nMetabolic Disorders: Results from PK-PD Study in Non-Human Primates,” Entera\nreported a single dose pharmacokinetic-pharmacodynamic study in non-human\nprimates:\n* EB618 exhibited robust bioavailability, with dose-proportional systemic\nexposure across three tested tablet strengths and low variability.\n* A dose-proportional pharmacologic effect on postprandial blood glucose\nlevels was observed.\n* EB618 was well tolerated, with no safety concerns identified, at doses\nexceeding the anticipated clinical dose range by more than tenfold.\nThese data support the continued clinical development of EB618 as a potential\nfirst-in-class oral once-daily GLP-1/glucagon receptor agonist for the\ntreatment of obesity and metabolic disorders.\n\nAbout Entera \nEntera is a clinical stage company focused on developing oral peptide and\nprotein replacement therapies for significant unmet medical needs where an\noral tablet form holds the potential to transform the standard of care. The\nCompany leverages a disruptive and proprietary technology platform (N-Tab(®))\nand its pipeline of first-in-class oral peptide programs. The Company’s most\nadvanced product candidate, EB613 (oral PTH(1-34)), is being developed as the\nfirst oral, osteoanabolic (bone building) once-daily tablet for osteoporosis.\nA placebo-controlled, dose-ranging phase 2 study of EB613 tablets (n = 161)\nmet primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera\nis also developing the first oral Long Acting PTH(1-34) tablet as a\nreplacement therapy for patients with hypoparathyroidism (EB612), the first\noral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the\ntreatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet\nas an injection-free alternative for patients suffering from rare\nmalabsorption conditions such as short bowel syndrome in collaboration with\nOPKO Health, Inc. For more information on Entera, visit www.enterabio.com or\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=pDfAmRcWDEMFksZFIgieS6G4HacB36HcrS7mdjmJ24FvBaY-ZW7EXFu2avcGNx7RB7s0oIOjEqA7yoW1m0lqwKDYqpLOVFKMsJF16T2Urz-JBUD6opKOw2TwHNBHZm-ENEq1AxnZ4cg2jP-PwYlIVLeZH1hhmQoitTsdgiXv3Bi2tvfTSkxGGSUYc4ftlnvJms9AsLdhM1gVK7IdtE1XCdSYdQzTmAOYgIKeH9Y_h3GB5pNp4cImliO0XWUPJSMWRV6Bh1ZsP3AoVChHvWQVLimyuMz_L8cOuQVSFVKa0PVqDyXy2l0OkvNdwAWuPquU9uWq06y__jtVtvryTvxs8T32QH-DbKhwFMuwiWM6ccrDidnMirECbEuj1iKwHL5AvT4bGFVrhrp7EnEbNqLSwp5hGlzOSlxnluNpePOz4Dcba2ZKric4H09CrGA3S_gcRv5Sp_4_YbAoYCHTaSmUXUJswnONEEqmNTkb78WOTuQrXr_jlmz4C5WFhN32B_kq_HgToE0Ag2poUbjkbg7hrudchKZov0tur9w5cMnZj4MdC0-0wZeTRAR3suWvPoxB2WJap0HWsFSDuZ6Ld2B7cTMYkk4e3th2-0YlPog0ENjxIO3eNDNiM0K4NT-h9hgNQvSe4W_SgSjccVHg70TTfJa3djJain6LVts8PfWsmpetOka_YvIBfSF1rWyzqVfp), Twitter\n(https://www.globenewswire.com/Tracker?data=EKvOYbp041zjEcsUHJPHYB_CV8zgWxW69mPtQHLWLXvjYgKV2BJ3Dv5FLa_jve0McgWbbvv78GMKCyqH2h1CJP8qh9UDbID9jb_T6pG2TMZUY19HMMdV08wn2XgUhoBEkJfarOAryWMo0vNqH_DY48Fcvdhz2VfwfMg4aty7OzF9oMLaj992K3KiTKkJeJvvVu5hsuakS-13qWO7dKdedb9ngCTzgxaUOGqnxoJAig3vB2fvV8HdffmOowusTYHiPGsthuJhUH4Nw8DJAd68r5M1qlNWns9658bxqhWa8MMZe2AnP0BAGeye_u9nld6tbRI6HFbaDeYyusNeKefxbDsdiF6Wc2isC8Gpvz87Z6OaDkPN7Z5tOfhPCAADlzHA6fi6kQdI9cV0b1SSaah1Ey5Dzz25sI16b53K1zys4EhwbbXGnzizAVu1WkRVFBn4EP_312LcJXAebhIXkIkvG-hmzh764sY8QAv80GbfHk7bOyAZNUAk0TsM9NlIHR0wz4x8GidXtbFDmMXDqosDRJisVn4WLRDGnkqLVC3DLZeMzcVPh6R-Yv26UraNuhdg5O7plK4F_b6cH7E25RtJ9CNT3dYqP823Y15dBjC6WTj95NujwACRDWyolE7pmsqKSTr3p0fiObzDrTrtXp1mSjmvxoZmFlAvBMWCZ8C3EnU=),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=lZhlc22UZkI32imqI-3lVp6Ap2GHcR3CWEp1VzwfxBh7Vz2N0ERAxERGUxrw7UVUvLtBAzgDTIp-bMrdrMqLSVqfudJ0yWPrPRupxbAyQErc7GYJbliTHTH-Fru-_s2YyW0hoVFhlAR_2CinOqKg_zckrZiqFYQgQhK7mFkEyTh7mjZhINiEzAfZnuT2HhdztV-vAFqgxNl22pamhVVqalVjrDNFVcqNIAAW5UCTpDu5PcBX-flnNYwSuPSLBVTrkmHKiDpmgfWkSunqJgvM98WbccmIKdDzKYiFoec1uh0gFOMVThVXPQw2dTWds-WgP7erTSZaB03sGcWm0WoyaTauyGA1qrHpZsxkQpptEye8j1XEoUZIZsBzHasE3VlsL_f1rI86q_hyaKBIZDbz7Ccp_lMPDb7B8TxXdP4wn6gzjFFwQPEoAdlLzb2WYPq6xRPs1bZDrVmDVwH-zqdBvGU-zI2cEXJmbgGNQTDVGWlAN3tLlhUhZBE8LMiolh36_MBhpCmKX2JqCwuA4b8OB-5qPg1Yk6FWMFGsgOqBGmaOFeBL0M-HpdErOPxuCMuDvv4W3Sk8VovW1V8zyMG_8E6kH3e97WdAoHqN3dKUmvkV1S4Pdhv8wZPyteriXoEGi5FPeBAdkTHwA128-122eyND4KLP2XuF_tyfarhBTEG4yR8eyTw9IRu4ne4QlQqF).\n\nCautionary Statement Regarding Forward Looking Statements\nVarious statements in this press release are “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nAll statements (other than statements of historical facts) in this press\nrelease regarding our prospects, plans, financial position, business strategy,\nclinical development activities, collaboration arrangements and expected\nfinancial and operational results are forward-looking statements. Words such\nas, but not limited to, “anticipate,” “believe,” “can,”\n“could,” “expect,” “estimate,” “design,” “goal,”\n“intend,” “may,” “might,” “objective,” “plan,”\n“predict,” “project,” “target,” “likely,” “should,”\n“will,” and “would,” or the negative of these terms and similar\nexpressions or words, identify forward-looking statements. Forward-looking\nstatements are based upon current expectations that involve risks, changes in\ncircumstances, assumptions and uncertainties. Forward-looking statements\nshould not be read as a guarantee of future performance or results and may not\nbe accurate indications of when such performance or results will be achieved.\nImportant factors that could cause actual results to differ materially from\nthose reflected in Entera’s forward-looking statements include, among\nothers: changes in the interpretation of clinical data; results of our\nclinical trials; the FDA’s interpretation and review of our results from and\nanalysis of our clinical trials; unexpected changes in our ongoing and planned\npreclinical development and clinical trials, the timing of and our ability to\nmake regulatory filings and obtain and maintain regulatory approvals for our\nproduct candidates; the potential disruption and delay of manufacturing supply\nchains; loss of available workforce resources, either by Entera or its\ncollaboration and laboratory partners; impacts to research and development or\nclinical activities that Entera may be contractually obligated to provide;\noverall regulatory timelines; the size and growth of the potential markets for\nour product candidates; the scope, progress and costs of developing Entera’s\nproduct candidates; Entera’s reliance on third parties to conduct its\nclinical trials; Entera’s ability to establish and maintain development and\ncommercialization collaborations; Entera’s operation as a development stage\ncompany with limited operating history; Entera’s competitive position with\nrespect to other products on the market or in development for the treatment of\nosteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic\nconditions and other disease categories it pursues; Entera’s ability to\ncontinue as a going concern absent access to sources of liquidity; Entera’s\nability to obtain and maintain regulatory approval for any of its product\ncandidates; Entera’s ability to comply with Nasdaq’s minimum listing\nstandards and other matters related to compliance with the requirements of\nbeing a public company in the United States; Entera’s intellectual property\nposition and its ability to protect its intellectual property; and other\nfactors that are described in the “Cautionary Statement Regarding\nForward-Looking Statements,” “Risk Factors” and “Management’s\nDiscussion and Analysis of Financial Condition and Results of Operations”\nsections of Entera’s most recent Annual Report on Form 10-K filed with the\nSEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q\nand Current Reports on Form 8-K. There can be no assurance that the actual\nresults or developments anticipated by Entera will be realized or, even if\nsubstantially realized, that they will have the expected consequences to, or\neffects on, Entera. Therefore, no assurance can be given that the outcomes\nstated or implied in such forward-looking statements and estimates will be\nachieved. Entera cautions investors not to rely on the forward-looking\nstatements Entera makes in this press release. The information in this press\nrelease is provided only as of the date of this press release, and Entera\nundertakes no obligation to update or revise publicly any forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except to the extent required by law.\n\nCompany Contact:\nIR@enterabio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cad5c2b9-1536-4364-aa1b-6b8216d3658f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXxXDM","title":"Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026","author":"Globe Newswire","ticker":"ENTX","created":"2026-06-16T12:33:11.097Z","tickers":["ENTX","OPK","5DT"],"exchange":"NASDAQ","article_body":"EB612, a first-in-class long-acting PTH(1-34) oral peptide  for\nhypoparathyroidism, produced robust bioavailability and sustained increases in\ncalcium across three preclinical models; IND is expected in late 2026\n\nEB618, a first-in-class dual GLP-1/glucagon oral receptor agonist\n(oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional\npharmacokinetics and a robust effect on blood glucose in non-human primates\n\nTEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX)\n(“Entera”), a leader in the development of oral peptides, reported\npreclinical data at ENDO 2026, the annual meeting of the Endocrine Society,\nfor its EB612 and EB618 pipeline programs. Both EB612 and EB618 programs are\nbeing co-developed with OPKO Health Inc. (NASDAQ: OPK).\n\n“The strength of these results underscores the consistency of our N-Tab(®)\nplatform to develop proprietary oral peptides across a myriad of targets and\nindications,” said Miranda Toledano, Chief Executive Officer of Entera.\n\nEB612: First-in-Class Oral Long-Acting PTH(1-34) Peptide Tablet for\nHypoparathyroidism\n\nEB612 is a proprietary first-in-class long-acting PTH(1-34) analog formulated\nwith Entera’s N-Tab(®) oral peptide platform.  As the first oral peptide\nreplacement therapy, EB612 aims to provide patients with an oral alternative\nto currently approved or development-stage peptides that require injections.\n\nIn a poster presentation entitled “Pre-Clinical Results for EB612:\nFirst-in-Class Oral Long-Acting PTH(1-34) Analog as Hormone Replacement Tablet\nfor Patients with Hypoparathyroidism,” Entera highlighted the following data\nfor EB612:\n* In the thyroparathyroidectomized (TPTx) rat model, the established and\nwidely used preclinical model of hypoparathyroidism, the long-acting PTH(1-34)\nanalog, dosed daily for 7 days, restored serum calcium and reduced phosphate\nto levels comparable to sham control animals.\n* In a minipig model, a single oral dose of EB612 reached maximal plasma\nlevels 2 to 3 hours post-dose, with drug remaining detectable in plasma for\nmore than three days. This sustained pharmacokinetic exposure was associated\nwith a rapid and long-lasting increase in serum Ca in all study animals. The\ncalcemic effect lasted for approximately three days.\n* In a non-human primate model, a single oral dose of EB612 produced a robust\nand sustained increase in serum calcium for approximately three days,\naccompanied by a correlating suppression of endogenous PTH levels.\nEB612 was well tolerated, with no safety concerns identified, and the calcemic\neffects were consistent with those reported for clinically validated\ninjectable PTH-replacement therapies for hypoparathyroidism.\n\nOngoing studies are advancing EB612 toward first-in-human clinical evaluation.\nAs announced in February 2026, Entera and OPKO expanded their collaboration to\nadvance EB612 on a 50/50 basis, with an intention to file an investigational\nnew drug (IND) application in late 2026.\n\nEB618: First-in-Class Oral Dual GLP-1/Glucagon receptor agonist\n(Oxyntomodulin) Tablet for Obesity and Metabolic Disorders\n\nOxyntomodulin (OXM) is a naturally occurring dual GLP-1/glucagon receptor\nagonist hormone that regulates appetite and glucose metabolism and promotes\nweight loss, with additional cardioprotective and anti-fibrotic properties;\nits therapeutic potential as a native hormone is limited by a short plasma\nhalf-life.\n\nThe EB618 tablet is a proprietary long-acting OXM analog formulated with\nEntera’s N-Tab(®) platform.\n\nIn a poster presentation at ENDO 2026 entitled “EB618, First-In-Class Oral\nTablet of Dual GLP-1/Glucagon Receptor Agonist for Patients with Obesity and\nMetabolic Disorders: Results from PK-PD Study in Non-Human Primates,” Entera\nreported a single dose pharmacokinetic-pharmacodynamic study in non-human\nprimates:\n* EB618 exhibited robust bioavailability, with dose-proportional systemic\nexposure across three tested tablet strengths and low variability.\n* A dose-proportional pharmacologic effect on postprandial blood glucose\nlevels was observed.\n* EB618 was well tolerated, with no safety concerns identified, at doses\nexceeding the anticipated clinical dose range by more than tenfold.\nThese data support the continued clinical development of EB618 as a potential\nfirst-in-class oral once-daily GLP-1/glucagon receptor agonist for the\ntreatment of obesity and metabolic disorders.\n\nAbout Entera \nEntera is a clinical stage company focused on developing oral peptide and\nprotein replacement therapies for significant unmet medical needs where an\noral tablet form holds the potential to transform the standard of care. The\nCompany leverages a disruptive and proprietary technology platform (N-Tab(®))\nand its pipeline of first-in-class oral peptide programs. The Company’s most\nadvanced product candidate, EB613 (oral PTH(1-34)), is being developed as the\nfirst oral, osteoanabolic (bone building) once-daily tablet for osteoporosis.\nA placebo-controlled, dose-ranging phase 2 study of EB613 tablets (n = 161)\nmet primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera\nis also developing the first oral Long Acting PTH(1-34) tablet as a\nreplacement therapy for patients with hypoparathyroidism (EB612), the first\noral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the\ntreatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet\nas an injection-free alternative for patients suffering from rare\nmalabsorption conditions such as short bowel syndrome in collaboration with\nOPKO Health, Inc. For more information on Entera, visit www.enterabio.com or\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=pDfAmRcWDEMFksZFIgieS6G4HacB36HcrS7mdjmJ24FvBaY-ZW7EXFu2avcGNx7RB7s0oIOjEqA7yoW1m0lqwKDYqpLOVFKMsJF16T2Urz-JBUD6opKOw2TwHNBHZm-ENEq1AxnZ4cg2jP-PwYlIVLeZH1hhmQoitTsdgiXv3Bi2tvfTSkxGGSUYc4ftlnvJms9AsLdhM1gVK7IdtE1XCdSYdQzTmAOYgIKeH9Y_h3GB5pNp4cImliO0XWUPJSMWRV6Bh1ZsP3AoVChHvWQVLimyuMz_L8cOuQVSFVKa0PVqDyXy2l0OkvNdwAWuPquU9uWq06y__jtVtvryTvxs8T32QH-DbKhwFMuwiWM6ccrDidnMirECbEuj1iKwHL5AvT4bGFVrhrp7EnEbNqLSwp5hGlzOSlxnluNpePOz4Dcba2ZKric4H09CrGA3S_gcRv5Sp_4_YbAoYCHTaSmUXUJswnONEEqmNTkb78WOTuQrXr_jlmz4C5WFhN32B_kq_HgToE0Ag2poUbjkbg7hrudchKZov0tur9w5cMnZj4MdC0-0wZeTRAR3suWvPoxB2WJap0HWsFSDuZ6Ld2B7cTMYkk4e3th2-0YlPog0ENjxIO3eNDNiM0K4NT-h9hgNQvSe4W_SgSjccVHg70TTfJa3djJain6LVts8PfWsmpetOka_YvIBfSF1rWyzqVfp), Twitter\n(https://www.globenewswire.com/Tracker?data=EKvOYbp041zjEcsUHJPHYB_CV8zgWxW69mPtQHLWLXvjYgKV2BJ3Dv5FLa_jve0McgWbbvv78GMKCyqH2h1CJP8qh9UDbID9jb_T6pG2TMZUY19HMMdV08wn2XgUhoBEkJfarOAryWMo0vNqH_DY48Fcvdhz2VfwfMg4aty7OzF9oMLaj992K3KiTKkJeJvvVu5hsuakS-13qWO7dKdedb9ngCTzgxaUOGqnxoJAig3vB2fvV8HdffmOowusTYHiPGsthuJhUH4Nw8DJAd68r5M1qlNWns9658bxqhWa8MMZe2AnP0BAGeye_u9nld6tbRI6HFbaDeYyusNeKefxbDsdiF6Wc2isC8Gpvz87Z6OaDkPN7Z5tOfhPCAADlzHA6fi6kQdI9cV0b1SSaah1Ey5Dzz25sI16b53K1zys4EhwbbXGnzizAVu1WkRVFBn4EP_312LcJXAebhIXkIkvG-hmzh764sY8QAv80GbfHk7bOyAZNUAk0TsM9NlIHR0wz4x8GidXtbFDmMXDqosDRJisVn4WLRDGnkqLVC3DLZeMzcVPh6R-Yv26UraNuhdg5O7plK4F_b6cH7E25RtJ9CNT3dYqP823Y15dBjC6WTj95NujwACRDWyolE7pmsqKSTr3p0fiObzDrTrtXp1mSjmvxoZmFlAvBMWCZ8C3EnU=),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=lZhlc22UZkI32imqI-3lVp6Ap2GHcR3CWEp1VzwfxBh7Vz2N0ERAxERGUxrw7UVUvLtBAzgDTIp-bMrdrMqLSVqfudJ0yWPrPRupxbAyQErc7GYJbliTHTH-Fru-_s2YyW0hoVFhlAR_2CinOqKg_zckrZiqFYQgQhK7mFkEyTh7mjZhINiEzAfZnuT2HhdztV-vAFqgxNl22pamhVVqalVjrDNFVcqNIAAW5UCTpDu5PcBX-flnNYwSuPSLBVTrkmHKiDpmgfWkSunqJgvM98WbccmIKdDzKYiFoec1uh0gFOMVThVXPQw2dTWds-WgP7erTSZaB03sGcWm0WoyaTauyGA1qrHpZsxkQpptEye8j1XEoUZIZsBzHasE3VlsL_f1rI86q_hyaKBIZDbz7Ccp_lMPDb7B8TxXdP4wn6gzjFFwQPEoAdlLzb2WYPq6xRPs1bZDrVmDVwH-zqdBvGU-zI2cEXJmbgGNQTDVGWlAN3tLlhUhZBE8LMiolh36_MBhpCmKX2JqCwuA4b8OB-5qPg1Yk6FWMFGsgOqBGmaOFeBL0M-HpdErOPxuCMuDvv4W3Sk8VovW1V8zyMG_8E6kH3e97WdAoHqN3dKUmvkV1S4Pdhv8wZPyteriXoEGi5FPeBAdkTHwA128-122eyND4KLP2XuF_tyfarhBTEG4yR8eyTw9IRu4ne4QlQqF).\n\nCautionary Statement Regarding Forward Looking Statements\nVarious statements in this press release are “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nAll statements (other than statements of historical facts) in this press\nrelease regarding our prospects, plans, financial position, business strategy,\nclinical development activities, collaboration arrangements and expected\nfinancial and operational results are forward-looking statements. Words such\nas, but not limited to, “anticipate,” “believe,” “can,”\n“could,” “expect,” “estimate,” “design,” “goal,”\n“intend,” “may,” “might,” “objective,” “plan,”\n“predict,” “project,” “target,” “likely,” “should,”\n“will,” and “would,” or the negative of these terms and similar\nexpressions or words, identify forward-looking statements. Forward-looking\nstatements are based upon current expectations that involve risks, changes in\ncircumstances, assumptions and uncertainties. Forward-looking statements\nshould not be read as a guarantee of future performance or results and may not\nbe accurate indications of when such performance or results will be achieved.\nImportant factors that could cause actual results to differ materially from\nthose reflected in Entera’s forward-looking statements include, among\nothers: changes in the interpretation of clinical data; results of our\nclinical trials; the FDA’s interpretation and review of our results from and\nanalysis of our clinical trials; unexpected changes in our ongoing and planned\npreclinical development and clinical trials, the timing of and our ability to\nmake regulatory filings and obtain and maintain regulatory approvals for our\nproduct candidates; the potential disruption and delay of manufacturing supply\nchains; loss of available workforce resources, either by Entera or its\ncollaboration and laboratory partners; impacts to research and development or\nclinical activities that Entera may be contractually obligated to provide;\noverall regulatory timelines; the size and growth of the potential markets for\nour product candidates; the scope, progress and costs of developing Entera’s\nproduct candidates; Entera’s reliance on third parties to conduct its\nclinical trials; Entera’s ability to establish and maintain development and\ncommercialization collaborations; Entera’s operation as a development stage\ncompany with limited operating history; Entera’s competitive position with\nrespect to other products on the market or in development for the treatment of\nosteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic\nconditions and other disease categories it pursues; Entera’s ability to\ncontinue as a going concern absent access to sources of liquidity; Entera’s\nability to obtain and maintain regulatory approval for any of its product\ncandidates; Entera’s ability to comply with Nasdaq’s minimum listing\nstandards and other matters related to compliance with the requirements of\nbeing a public company in the United States; Entera’s intellectual property\nposition and its ability to protect its intellectual property; and other\nfactors that are described in the “Cautionary Statement Regarding\nForward-Looking Statements,” “Risk Factors” and “Management’s\nDiscussion and Analysis of Financial Condition and Results of Operations”\nsections of Entera’s most recent Annual Report on Form 10-K filed with the\nSEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q\nand Current Reports on Form 8-K. There can be no assurance that the actual\nresults or developments anticipated by Entera will be realized or, even if\nsubstantially realized, that they will have the expected consequences to, or\neffects on, Entera. Therefore, no assurance can be given that the outcomes\nstated or implied in such forward-looking statements and estimates will be\nachieved. Entera cautions investors not to rely on the forward-looking\nstatements Entera makes in this press release. The information in this press\nrelease is provided only as of the date of this press release, and Entera\nundertakes no obligation to update or revise publicly any forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except to the extent required by law.\n\nCompany Contact:\nIR@enterabio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cad5c2b9-1536-4364-aa1b-6b8216d3658f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-16T12:33:11.139509305Z","server_sent_at_ms":1781613191139},"received_at":"2026-06-16T12:33:11.200Z","source_url":"https://www.globenewswire.com/news-release/2026/06/16/3312598/0/en/Entera-Reports-Robust-Preclinical-Data-for-EB612-Oral-LA-PTH-1-34-for-Hypoparathyroidism-and-EB618-Oral-GLP-1-Glucagon-for-Obesity-at-ENDO-2026.html"},"analysis":{"id":"54456","press_release_id":"65043","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Entera Bio reported positive preclinical data for two pipeline programs, EB612 for hypoparathyroidism and EB618 for obesity, at the ENDO 2026 conference.\n\nEB612 demonstrated robust bioavailability and sustained calcium increases in three preclinical models, supporting an IND filing expected in late 2026.\n\nEB618 showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates, with no safety concerns identified at doses exceeding the anticipated clinical range by more than tenfold.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Preclinical data validates N-Tab platform, but clinical trials remain the key hurdle."},"keyFigures":{"customDimensions":{"eb618_tested_strengths":3,"eb612_detection_duration":"more than three days","eb612_treatment_duration":"7 days","eb618_preclinical_dose_range":"exceeding anticipated clinical dose range by more than tenfold","eb612_calcemic_effect_duration":"approximately three days"}},"quotedText":"The strength of these results underscores the consistency of our N-Tab(®) platform to develop proprietary oral peptides across a myriad of targets and indications","namedEntities":{"people":[{"name":"Miranda Toledano","role":"Chief Executive Officer"}],"products":["EB612","EB618","N-Tab","EB613","Oxyntomodulin"],"companies":[{"name":"Entera Bio Ltd.","ticker":"ENTX"},{"name":"OPKO Health Inc.","ticker":"OPK","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Positive preclinical data for two pipeline assets (EB612, EB618) presented at a major medical conference (ENDO). While encouraging, preclinical results are inherently risky and do not guarantee clinical success, capping the impact score below binary events like FDA approvals."},"tickerRelevance":{"others":[{"ticker":"OPK","relevance":"partner"}],"primary":"ENTX"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"conference":"ENDO_2026","tickerTier":"small-cap","eventGravity":"preclinical_data_presentation","sectorWeight":"biotech"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Entera Bio reported positive preclinical data for two pipeline programs, EB612 for hypoparathyroidism and EB618 for obesity, at the ENDO 2026 conference.\n\nEB612 demonstrated robust bioavailability and sustained calcium increases in three preclinical models, supporting an IND filing expected in late 2026.\n\nEB618 showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates, with no safety concerns identified at doses exceeding the anticipated clinical range by more than tenfold.","key_figures":{"customDimensions":{"eb618_tested_strengths":3,"eb612_detection_duration":"more than three days","eb612_treatment_duration":"7 days","eb618_preclinical_dose_range":"exceeding anticipated clinical dose range by more than tenfold","eb612_calcemic_effect_duration":"approximately three days"}},"named_entities":{"people":[{"name":"Miranda Toledano","role":"Chief Executive Officer"}],"products":["EB612","EB618","N-Tab","EB613","Oxyntomodulin"],"companies":[{"name":"Entera Bio Ltd.","ticker":"ENTX"},{"name":"OPKO Health Inc.","ticker":"OPK","relationship":"partner"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-16T13:33:06.528Z","global_importance":25,"audience_relevance":20,"importance_components":{"conference":"ENDO_2026","tickerTier":"small-cap","eventGravity":"preclinical_data_presentation","sectorWeight":"biotech"}},"durationMs":60309,"modelName":"george-droid-qwen-72b"}}